RxDoctor Payments Data

Harvinder Kohli

Neurology · Hilton Head, SCNPI 1376560177

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.8% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Genentech USA, Inc. at 41.2% of the total. Reporting peaked in 2019 at $80 and has fallen 74.6% since, to $20 in 2024. That places this record below the midpoint for neurology clinicians in SC, where the typical reported total is $752.

$161in general payments, 2019–2025

Across 7 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$66
  • AstraZeneca$20
  • Argenx US, Inc.$20
  • Novartis$15
  • Takeda Pharmaceuticals U.S.A., Inc.$15
  • Tanabe Pharma America, Inc.$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$14892%
  • Education$138%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$161 in reported general payments places this provider in the 25th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina →

Medicare billing

Part B allowed, 2024
$118,849
Medicare patients
626
Services billed
1,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate20$19,350
Ajovy AutoinjectorFremanezumab-Vfrm15$10,579
Gabapentin440$10,566
Aimovig AutoinjectorErenumab-Aooe12$6,542
Primidone169$5,808
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone29$5,590
Rivastigmine27$5,083
Lacosamide43$4,671
Levetiracetam157$4,538
Donepezil Hcl316$4,033
Mycophenolate Mofetil13$4,001
Carbidopa-LevodopaCarbidopa/Levodopa156$3,692
Oxcarbazepine26$3,262
Carbamazepine ErCarbamazepine15$3,056
Pyridostigmine Bromide26$2,911

Paid to pharmacies, not to this prescriber.

Other neurology in Hilton Head

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →